Does valerian root help with sleep disruption during perimenopause?

Sleep disruption is valerian root's strongest and best-documented application, and it has a particularly clear mechanistic fit with the hormonal changes that drive perimenopausal insomnia.

A meta-analysis by Bent et al. (2006) reviewed 16 controlled studies and found that valerian improved subjective sleep quality with no serious adverse effects reported. The effect size was described as modest, meaning valerian is not as potent as pharmaceutical sleep medications, but the favorable safety profile makes it a meaningful option for women who want to avoid or reduce reliance on prescription sedatives.

The mechanism is highly relevant to perimenopause specifically. Progesterone is converted in the brain to allopregnanolone, a neurosteroid that positively modulates GABA-A receptors, the main braking system of the nervous system. Allopregnanolone promotes sleep onset, reduces nighttime waking, and supports deep non-REM sleep stages. As progesterone declines during perimenopause, allopregnanolone falls with it, and the nervous system loses a key inhibitory signal. Sleep becomes lighter, more fragmented, and harder to maintain.

Valerian's primary active compound, valerenic acid, inhibits the enzyme that breaks down GABA at GABA-A receptors, allowing more GABA to remain active. This supports the inhibitory signaling that declining progesterone has reduced. Valerian also has adenosine receptor activity, which may contribute to sleep promotion through a second, independent pathway. Adenosine builds up during waking hours and promotes sleep pressure, and valerian may enhance this signal.

For best results, valerian is taken 30 to 60 minutes before bed rather than at the moment of trying to sleep. Consistency matters: several studies suggest that valerian's effects build over one to two weeks of regular use rather than working acutely on the first night. This sets it apart from fast-acting sleep medications and means that inconsistent use is unlikely to show a benefit.

An earlier randomized controlled trial by Leathwood et al. (1982) found that valerian reduced sleep onset time. Dorn (2000) compared valerian to oxazepam, a benzodiazepine, for insomnia and found comparable subjective improvement, which speaks to valerian's relevance even against pharmaceutical comparators.

Night sweats and hot flashes are a major driver of sleep fragmentation during perimenopause and are separate from the neurological insomnia that valerian addresses most directly. If vasomotor symptoms are waking you multiple times per night, valerian alone may not be sufficient, though it may reduce the difficulty of returning to sleep after a wake episode by maintaining a calmer baseline state.

It is also worth noting that valerian can cause morning grogginess at higher doses, particularly in the early weeks of use. This side effect usually diminishes with continued use and can be minimized by taking valerian earlier in the evening rather than just before bed.

Studies have generally used standardized extracts in the range of 300 to 600 mg. Your healthcare provider can help determine what form and dose may be appropriate for your situation.

Tracking how your symptoms shift over time, using a tool like PeriPlan, can help you spot patterns, including whether sleep quality is genuinely improving and which nighttime symptoms are disrupting your rest most often.

Safety and interactions to know about

Valerian is generally considered safe for short-term use of four to eight weeks. Side effects include drowsiness, headache, vivid dreams, and morning grogginess at higher doses. The most critical safety concern is interaction with CNS depressants. Combining valerian with alcohol, benzodiazepines, opioids, antihistamines, or prescription sleep medications produces additive sedation that can be dangerous. Very high doses have been associated with rare liver concerns. Do not drive after taking valerian. It is not recommended during pregnancy, and the safety of long-term use beyond eight weeks has not been established.

When to talk to your doctor

Sleep disruption during perimenopause that is severe, occurring nightly, or significantly impairing daytime functioning warrants medical evaluation. A provider can assess whether night sweats and hot flashes are the primary driver, evaluate for sleep apnea (which worsens during perimenopause and is often underdiagnosed in women), and discuss whether cognitive behavioral therapy for insomnia (CBT-I) or other treatments might be appropriate. CBT-I in particular has strong evidence as a first-line treatment for chronic insomnia and can be more durable than supplement-based approaches.

This content is for informational purposes only and does not replace medical advice. Always consult your healthcare provider about your specific situation.